Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rebecca Johnson

Physician Assistant, Medical Spokane, WA Physician Assistant

NPI 1083864045 CMS profile 10992137

220 E Rowan Ave, Suite 300, Spokane, WA 99207

Open in the dashboard

General payments

$13,645

804 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebecca Johnson of Spokane, WA is reported in the CMS Open Payments database as having received $13,645 across 804 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,054 149
2024 General $2,476 125
2023 General $2,323 131
2022 General $2,956 190
2021 General $2,836 209

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Johnson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Rebecca Johnson were reported at $3,054. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Rebecca Johnson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,836 $156 $41–$563 $132
2022 $2,956 $185 $55–$649 $149
2023 $2,323 $199 $58–$717 $160
2024 $2,476 $206 $62–$740 $164
2025 $3,054 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,401 84 payments
  2. AstraZeneca Pharmaceuticals LP $1,333 66 payments
  3. Amgen Inc. $1,123 61 payments
  4. Teva Pharmaceuticals USA, Inc. $1,112 47 payments
  5. Novo Nordisk Inc $747 65 payments
  6. GlaxoSmithKline, LLC. $746 79 payments
  7. Janssen Pharmaceuticals, Inc $668 36 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $624 45 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $602 32 payments
  10. Pfizer Inc. $588 35 payments
  11. Other $4,700 254 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,358 800 payments
  2. Education $286 4 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $716 76 payments
  2. BREZTRI $695 25 payments
  3. Ozempic $602 55 payments
  4. UBRELVY $585 32 payments
  5. XARELTO $585 32 payments
  6. QULIPTA $569 30 payments
  7. Otezla $528 27 payments
  8. RYBELSUS $514 51 payments
  9. Austedo XR $481 24 payments
  10. FARXIGA $460 10 payments
  11. Other $12,445 710 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 164 drugs

Part D claims

9,394

Median for Physician Assistant: 241

Drug cost

$831,359

Median for Physician Assistant: $4,110

Branded share of claims

23%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 94 $125,329
Mounjaro Tirzepatide Brand 90 $102,155
Eliquis Apixaban Brand 72 $80,593
Xarelto Rivaroxaban Brand 57 $66,952
Ozempic Semaglutide Brand 56 $65,969
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $38,157
Farxiga Dapagliflozin Propanediol Brand 30 $33,624
Januvia Sitagliptin Phosphate Brand 29 $30,935
Myrbetriq Mirabegron Brand 30 $23,565
Prolia Denosumab Brand 12 $21,435

The 10 drugs with the highest cost, of 164 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$44,585

Of which drugs: $122

Medicare patients

195

Average age 76

Services billed

1,183

147 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 28%
Chronic kidney disease 21%
Atrial fibrillation 18%
Depression 18%
Heart failure 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 109 $75

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$189 — —
REXULTI
$178 — —
XARELTO
$164 57 —
Austedo XR
$134 — —
JARDIANCE
$122 94 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

804 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record